linvoseltamab
2 abstracts
Abstract
Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).Org: Mayo Clinic, University Medical Center Hamburg-Eppendorf, Regeneron Pharmaceuticals, Inc., EVERSANA, Burlington, ON, Canada, Mount Sinai Hospital-Breast Medical Oncology,